Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23995488 | 1.00 | MDM2 (0.49) | MDM2HTR2AHTR2CHTR2BSLC6A3 | |
| SCHEMBL27882712 | 0.79 | MDM2 (0.40) | MDM2HTR2AHTR2CHTR2BSLC6A3 | |
| SCHEMBL16232201 | 0.79 | KDM1A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL17189669 | 0.79 | KDM1A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL1993581 | 0.79 | HTR2A (0.44) | MDM2HTR2AHTR2CHTR2BSLC6A3 | |
| SCHEMBL26696189 | 0.79 | KDM1A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL25004706 | 0.79 | KDM1A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL24974216 | 0.79 | KDM1A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL21503510 | 0.79 | KDM1A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL26404238 | 0.79 | KDM1A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | MDM2 2083/4885HTR2A 1593/4885HTR2C 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.